BIOCRYST PHARMACEUTICALS INC BCRX revenue by segment, product and geography
In its fiscal year ending 2025-12-31, BIOCRYST PHARMACEUTICALS INC reported revenue across 1 business segments; the largest, Reportable Segment, was $875M, 100.0% of the filed sum (+94.1% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Reportable Segment$875M100.0%+94.1% yoy
Members sum to the consolidated $875M for this period.
- Product$623Mshare n/a+40.8% yoy
- ORLADEYO$602Mshare n/a+37.5% yoy
- License And Other Revenues$252Mshare n/a+3028.9% yoy
- License$244Mshare n/ano prior
- Other Income From Contract With Customer$29Mshare n/a+122.3% yoy
- Collaborative And Other Research And Development$7.71Mshare n/a-4.2% yoy
member sum exceeds the consolidated figure: this axis carries more than one breakdown, so shares are not computed.
- Reportable Segment$156M100.0%+7.5% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.